These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20350481)

  • 1. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?
    Fernandez D; Perl A
    Discov Med; 2010 Mar; 9(46):173-8. PubMed ID: 20350481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway.
    He J; Ma J; Ren B; Liu A
    Semin Arthritis Rheum; 2020 Apr; 50(2):314-320. PubMed ID: 31796213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus.
    Zhao X; Wang S; Wang S; Xie J; Cui D
    Clin Immunol; 2022 Dec; 245():109153. PubMed ID: 36265758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients.
    Murayama G; Chiba A; Kuga T; Makiyama A; Yamaji K; Tamura N; Miyake S
    Rheumatology (Oxford); 2020 Oct; 59(10):2992-3002. PubMed ID: 32160289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b
    Shi G; Li D; Li X; Ren J; Xu J; Ding L; Dou H; Hou Y
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):1-13. PubMed ID: 30292636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
    Gu Z; Tan W; Ji J; Feng G; Meng Y; Da Z; Guo G; Xia Y; Zhu X; Shi G; Cheng C
    Aging (Albany NY); 2016 May; 8(5):1102-14. PubMed ID: 27048648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus.
    Kato H; Perl A
    Arthritis Rheumatol; 2018 Mar; 70(3):427-438. PubMed ID: 29161463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus.
    Muhammad Yusoff F; Wong KK; Mohd Redzwan N
    Autoimmunity; 2020 Feb; 53(1):8-20. PubMed ID: 31771364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment.
    Zhang J; Guo Q; Dai D; Yu J; Wang L; Wu Z; Ding H; Shen N; Duan Y
    Biomaterials; 2022 Oct; 289():121766. PubMed ID: 36087549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.
    Oaks Z; Winans T; Huang N; Banki K; Perl A
    Curr Rheumatol Rep; 2016 Dec; 18(12):73. PubMed ID: 27812954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal energy metabolism in the pathogenesis of systemic lupus erythematosus.
    Cao S; Jiang J; Yin H; Wang L; Lu Q
    Int Immunopharmacol; 2024 Jun; 134():112149. PubMed ID: 38692019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines in systemic lupus erythematosus: far beyond Th1/Th2 dualism lupus: cytokine profiles.
    Guimarães PM; Scavuzzi BM; Stadtlober NP; Franchi Santos LFDR; Lozovoy MAB; Iriyoda TMV; Costa NT; Reiche EMV; Maes M; Dichi I; Simão ANC
    Immunol Cell Biol; 2017 Oct; 95(9):824-831. PubMed ID: 28649995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
    Wong M
    Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony.
    Foster KG; Fingar DC
    J Biol Chem; 2010 May; 285(19):14071-7. PubMed ID: 20231296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunometabolism and systemic lupus erythematosus].
    Xiao YB; Guo MY; Zuo XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1120-1124. PubMed ID: 30562794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis.
    Caza T; Wijewardena C; Al-Rabadi L; Perl A
    Transl Res; 2022 Jul; 245():55-81. PubMed ID: 35288362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.
    Fernandez D; Bonilla E; Mirza N; Niland B; Perl A
    Arthritis Rheum; 2006 Sep; 54(9):2983-8. PubMed ID: 16947529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling abnormalities in systemic lupus erythematosus as potential drug targets.
    Fernandez D; Bonilla E; Phillips P; Perl A
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):305-11. PubMed ID: 17214576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.
    Powell JD; Delgoffe GM
    Immunity; 2010 Sep; 33(3):301-11. PubMed ID: 20870173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell and B-cell signaling biomarkers and treatment targets in lupus.
    Perl A; Fernandez DR; Telarico T; Doherty E; Francis L; Phillips PE
    Curr Opin Rheumatol; 2009 Sep; 21(5):454-64. PubMed ID: 19550330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.